Eastern Europe is presented as a region where hepatitis C virus infection is more prevalent than in Western Europe, making it an important geographic context for understanding the distribution, detection, and management of chronic hepatitis C. Its significance in the book is epidemiological rather than scenic: the region appears within a map of unequal infection burdens and within the broader history of hepatitis C in hemodialysis populations.

Epidemiological Setting

Eastern Europe is included among the areas with higher hepatitis C prevalence. While prevalence in Western Europe is described as ranging from 0.4% to 3%, prevalence rises in Eastern Europe and the Middle East, reaching as high as 13% in Egypt. This contrast places Eastern Europe on the higher-prevalence side of the book’s regional comparison and helps explain why hepatitis C remains a substantial public-health concern even though many chronically infected people do not know that they carry the virus.

The regional pattern is part of a worldwide burden estimated at roughly 3% of the population, with the number of chronically infected people potentially exceeding 170 million. The evidence does not assign a single cause to Eastern Europe’s higher prevalence, but it situates the region within a history in which transfusion-related exposure, injection practices, unsafe medical procedures, and other parenteral routes were central concerns. After systematic blood-product screening, the residual transfusion risk became extremely low, shifting attention toward other routes and toward the quality of medical infection-control systems.

Chronic Kidney Disease Context

The book also connects hepatitis C epidemiology with kidney disease. Across studied populations, HCV-infected patients have a higher risk of chronic kidney disease, and the virus has been associated with both glomerular lesions and a shorter time to progression toward advanced kidney disease. In one United States study, 18,002 patients with HCV infection were compared with 25,137 controls who had an estimated glomerular filtration rate above 60 at baseline; HCV infection was associated with a greater risk of developing chronic kidney disease stages 3–5. Another comparison found chronic kidney disease in 9.6% of anti-HCV-positive patients versus 5.1% of HCV-negative patients, with higher baseline viral load independently predicting chronic kidney disease.

These findings are not presented as an Eastern European cohort specifically, but they clarify why regional prevalence matters beyond liver disease. HCV infection can coexist with significant renal injury even when severe liver disease is absent. Patients with HCV-associated glomerulonephritis are described as serum HCV RNA positive, and the prevalence of HCV seropositivity among patients with membranoproliferative glomerulonephritis has been reported to be about ten times that observed among HCV-negative patients. The geographic burden therefore intersects with a clinical burden involving proteinuria, albuminuria, chronic kidney disease, and eventual end-stage renal disease.

Hemodialysis and Transmission

Eastern Europe belongs to the broader international setting in which hepatitis C in hemodialysis was historically common. When serological tests became available, hemodialysis patients were recognized as a high-risk group, partly because of the earlier use of transfusions and partly because evidence pointed toward continuing nosocomial transmission within dialysis units. Prevalence correlated strongly with time on dialysis in some studies, remained substantial among patients who had never received transfusions, and was higher in hemodialysis than in peritoneal dialysis or home hemodialysis.

The decline in transfusion risk did not eliminate the problem. In Western countries, the estimated risk of post-transfusion hepatitis C fell from about 0.5% per blood unit in the 1980s to approximately 0.0001%, or one case per million blood units, after improvements in donor screening and blood safety. As transfusion became less plausible as the principal explanation for new infections, attention turned to failures in infection-control practice inside dialysis units. Molecular studies using variable regions of the HCV genome identified closely related viral isolates among patients treated in the same units, providing phylogenetic evidence of nosocomial transmission even when the precise route could not be reconstructed.

The evidence favors strict hygiene rather than routine isolation or dedicated machines. A systematic review found that all twenty molecular-virology studies considered failures in infection-control procedures the probable cause of new cases, while only one regarded transmission through the internal fluid pathway of a dialysis machine as possible. In eighteen studies, some or all newly infected patients did not share a machine with the presumed source patient, suggesting that the internal machine circuit played at most a small role. The recommended prevention strategy centers on handwashing or alcohol-based hand rub when appropriate, disposable gloves, disposal of single-use items, disinfection or patient dedication of nondisposable equipment, cleaning of dialysis-station surfaces, safe waste management, and regular observational audits.

Transplantation and Regional Significance

The epidemiological importance of Eastern Europe also has implications for transplantation policy. HCV infection adversely affects survival in both dialysis and transplant populations, and 10% to 25% of kidney-transplant candidates may have advanced liver injury, including cirrhosis, when evaluated before transplantation. Candidates should therefore undergo screening for anti-HCV antibody and, where appropriate, active viremia through nucleic acid testing. Patients with active infection require assessment of liver fibrosis, with liver biopsy described as the gold standard when advanced disease must be evaluated, and those with established or decompensated cirrhosis may need referral for consideration of combined liver-kidney transplantation.

HCV-positive kidneys have historically been controversial, but long-term center and registry experience suggests that kidneys from HCV-positive donors can be used safely in HCV-positive recipients who have consented in advance and are positive for HCV RNA while waiting for transplantation. The safety of this approach may be improved by matching donor and recipient viral genotypes, although the evidence notes that genotype information has often been unavailable. Because HCV prevalence is falling and treatment before listing is becoming more proactive, suitable recipients for HCV-positive kidneys may become less common, increasing the risk that usable organs will be discarded. The resulting policy debate extends beyond any one region: it concerns how epidemiological change, viral status, waiting time, organ shortage, and informed consent should shape transplantation decisions.